Journal of Pharmacoeconomics and Pharmaceutical Management 2015. 1(3/4):59-60.

Prior authorization by the Health Insurance Organizations in Iran
Mehrnaz Kheirandish, Zahra Gharibnaseri, Fatemeh Soleymani, Abbas Kebriaeezadeh


Background: Health care improvement has had a critical role in increasing life expectancy throughout the world. The expenditures of research and development and also
marketing for new pharmaceutical products are much higher than already existing medicines, resulting in higher prices for the former products. Therefore governments and
health insurance organizations are interested in implementing policies that control drug prescription and utilization. One of these policies is Prior Authorization (PA). The
main goal of PA is to reduce drug expenditures by substituting expensive medicines with less costly ones. PA policy has both scientific and economical aspects. The aim of
this article is to assess the state of implementation of PA policy in Iran. There are several bodies to regulate medicines and their price in Iranian pharmaceutical market.
There are two main insurance companies in Iran with similarities and differences in implementing this policy. Price ceiling and Reference Based Pricing are two main
methods for implementing PA policy in Iran.


Prior Authorization, Insurance organization, Drug expenditure, Medicines’ price.

Full Text:



(1) Zasimova L. Public policy and access to new drugs: evidence from

Russian pharmaceutical market, PEI Electronic Publications 2/2010.

(2) The Henry J. Kaiser Family Foundation, Prescription Drug Trends, May

(3) Lapenesee KT. Analysis of a Prescription Drug Prior Authorization

Program in a Medicaid Health Maintenance Organization, J

Managed Care Pharm.2003; 9(1): 36-44.

(4) OECD. OECD Health Data 2006: Statistics and indicators for 30

countries. Paris: OECD, 2006.

(5) Mary Beth Hamel, Arnold M. Epstein, Prior-Authorization Programs

for Controlling Drug Spending. N Engl J Med. 2004; 351; 21.

(6) Comprehenive guide in Pharmacies, Davood Feyzi, Mahnaz

Mazandarani, Rouzbahan Press, p155-136, 2012.

(7) Puig-Junoy J, Moreno-Torres I. Impact of pharmaceutical prior

authorization policies; a systematic review of the literature.

Pharmacoeconomics. 2007; 25 (8):637-648.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.